Incyte Analyst Ratings
Oppenheimer Maintains Incyte(INCY.US) With Buy Rating, Cuts Target Price to $81
Goldman Sachs Adjusts Price Target on Incyte to $61 From $60, Maintains Neutral Rating
Incyte Analyst Ratings
Incyte Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Incyte (INCY)
Incyte Analyst Ratings
Incyte's Share Buyback Program: A Buy Rating and Fundamental Value Increase
Incyte's Strategic Financial Decisions and Market Positioning: A Hold Rating Analysis
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Incyte (INCY) and Ventyx Biosciences (VTYX)
Incyte's Resilient Demand and Strong Financials Justify Buy Rating Despite Q1 Sales Dip
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), TransMedics Group (TMDX) and Incyte (INCY)
Incyte Analyst Ratings
Citigroup Adjusts Price Target on Incyte to $80 From $81
RBC Capital Reaffirms Their Hold Rating on Incyte (INCY)
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Exelixis (EXEL)
Truist Securities Trims Incyte's Price Target to $83 From $84, Buy Rating Maintained
Incyte's Strategic Acquisition and Promising Pipeline Secure Buy Rating
Oppenheimer Sticks to Its Buy Rating for Incyte (INCY)
Incyte Analyst Ratings